Cannabis Science, Inc. (CBIS) Proud to Announce 4/20 Success! Opening of the First CBIS Cali Rx Location

“Friday’s 4/20 opening of the CBIS Cali RX location is a significant milestone for our Company,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, Chief Executive Officer (CEO), and Co-founder. “This is a beautiful, state-of-the-art, retail facility and connects Cannabis Science directly with all patients and doctors.”

“It’s tough to be in two places at the same time, but I’m working on it! ‘Due to the 4/20 Industrial Hemp court case date in the Company’s lawsuit against San Juaquin County, CA, as well as the recent depositions related to this case, Mr. Dabney and Cannabis Science’s senior executive team did not attend the soft opening of the CBIS Cali RX location on Ventura Boulevard.’ It was quite fitting that our date in U.S. Federal Court fell on April 20th,” stated Mr. Dabney. “I believe we had a good day in court last Friday, and we look forward to successfully pleading our case in the months to come.”

“We’ll get some cool signage up, get some new promo packages together, and get this party started! ‘Mr. Dabney and his team will host an Educational Expo upon his return to Los Angeles in the coming week at the new CBIS Cali RX location on Ventura Boulevard to discuss the Company’s major initiatives, including Cannabis Science’s drug-development consortium, and iCannabinoid, the Company’s social media and educational interactive online platform. The Company will also discuss scholarship programs for educational opportunities available through Cannabis Science’s partners, including American States University, American Heritage University School of Law, and the Raymond C. Dabney University.’ This is going to be fun!” concluded Mr. Dabney.

“The opening of the CBIS Cali RX location is an important part of Cannabis Science’s growth strategy. The CBIS Cali RX location will showcase Cannabis Science and Cali RX brands of high-quality cannabinoid and cannabis-based products and accessories for patients, doctors, and the consuming public. These products will range from pills, creams, extracts, sprays, tinctures, edibles, balms, patches, oils, raw products, and merchandise. The locations will also showcase other brands as well, in order to provide the widest possible selection of products for the Company’s patient community,” stated Dr. Allen Herman, Cannabis Science Inc., Chief Medical Officer, (CMO).

The CBIS Cali RX location on Ventura Boulevard will benefit from being located on one of the primary east-to-west thoroughfares in the San Fernando Valley. Ventura Boulevard is one of the oldest routes in the San Fernando Valley, as it was originally a part of the El Camino Real (the trail between Spanish missions). Historically, local and small shops have concentrated and thrived along Ventura Boulevard.

Cannabis Science encourages its customers to inquire about iCannabinoid, the Company’s online, high-tech social platform, at all locations. Cannabis Science’s aim is to have a fully-integrated community, by providing the experience of brick-and-mortar locations, as well as an online community for sharing experiences with medical marijuana and learning about the industry.

To connect, learn, and share; please visit our website at:

https://icannabinoid.com/

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.